Drugs / interferon gamma
interferon gamma
also known as
IFN-γ · IFN-g · gamma interferon · IFN-gamma · IFN-y · Immukine · interferon gamma-1b · NSC-600662 · +6 more
Trials 24
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials · 1 met primary | ||||||
| Phase 1 | NCT03056599 | Dec 2016 → Jul 2021 | soft tissue sarcoma | Presage Biosciences | Completed | Met primary |
| Phase 1 | NCT02614456 | Dec 2015 → Jun 2019 | cancer | Fox Chase Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT02197169 | Sep 2014 → Mar 2018 | malignant glioma | DNAtrix, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00977145 | Nov 2009 → Oct 2012 | melanoma | Craig L Slingluff, Jr | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00004016 | Apr 1999 → ? | cutaneous melanoma | University of Rochester | Completed | No outcome recorded |
| Phase 1 | NCT00004032 | Oct 1997 → Apr 2004 | malignant epithelial tumor of ovary | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05065905 | Jan → Mar 2006 | AIDS, coinfection, pulmonary tuberculosis | SPP Pharmaclon Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT00332930 | Sep 2002 → Sep 2003 | HIV infectious disease | Kirby Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT00002637 | Jan 1995 → Feb 2001 | prostate cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 28 trials · 1 missed | ||||||
| Phase 2 | NCT00148863 | Jun 2004 → Aug 2007 | chronic hepatitis C virus infection | French National Agency for Research on AIDS and Viral Hepatitis | Completed | Missed primary |
| Phase 2 | NCT00501644 | Jan 2003 → Jan 2009 | fallopian tube cancer, ovarian cancer, peritoneum cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00244179 | Jan 2003 → ? | reactive arthritis | Charite University, Berlin, Germany | Unknown | No outcome recorded |
| Phase 2 | NCT00021567 | Jul 2001 → Jun 2002 | Mycobacterium avium complex disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00024271 | May 2001 → ? | malignant mesothelioma | Herbert Irving Comprehensive Cancer Center | Unknown | No outcome recorded |
| Phase 2 | NCT00001905 | Apr 1999 → Mar 2002 | leukocyte adhesion deficiency 1 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00001407 | May 1994 → May 2003 | pneumonia, pulmonary tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00001318 | Aug 1992 → Nov 2000 | mycobacterial infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00538811 | — | hepatitis C virus infection | Aga Khan University | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT05843786 | Jun 2023 → Jul 2027 expected | — | Hospices Civils de Lyon | Recruiting | No outcome recorded |
| Phase 3 | NCT01270490 | Jan 2011 → Jan 2013 | candidemia | Radboud University Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT00004402 | Nov 1999 → Jun 2000 | osteopetrosis | FDA Office of Orphan Products Development | Completed | No outcome recorded |
| Phase 3 | NCT00001296 | Feb 1992 → Oct 2000 | melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00001317 | May 1992 → Jul 2001 | chronic granulomatous disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05395702 | May 2017 → Jul 2018 | pneumonia | SPP Pharmaclon Ltd. | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT00006113 Background | Jun 1999 → May 2003 | cutaneous melanoma | University of Southern California | Terminated | No outcome recorded |
| Phase 2/3 | NCT03984890 Background | Aug 2019 → Dec 2021 | chronic granulomatous disease | Children's Hospital of Fudan University | Completed | No outcome recorded |
| Phase 3 | NCT01649921 Comparator | Nov 2012 → Dec 2016 | infectious disease with sepsis | Radboud University Medical Center | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-11-10 | Nektar Therapeutics | Results Nektar Therapeutics Presents Preclinical Data from Novel PEGylated Interferon Gamma Program, NKTR-288, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting nektar.com ↗
The presentation today showed the sustained pharmacological properties of NKTR-288 relative to native cytokine, including durable exposure and induction of the well characterized interferon gamma response. |
All press releases naming this drug 3 releases
Evidence & citations 18 cited values
Every value below carries the sentence it was read from. 29 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | interferon gamma | “Recombinant interferon-gamma is a genetically engineered form of a substance normally produced by the body and is used to boost immune function.” NCT00001407 ↗28“Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma” NCT00977145 ↗ “a single injection of DNX-2401 was followed by interferon gamma (IFN-γ).” NCT02197169 ↗ “Anti-tuberculosis drugs, interferon-gamma” NCT03984890 ↗ |
| Known as | gamma interferon | “In one or two patients on the drug, blood will be drawn frequently following one injection of gamma interferon (just before the injection and again at 0.25, 0.5, 1, 6, 12, 18,...” NCT00001407 ↗ |
| Known as | IFN-g | “Tumor Necrosis Factor (Knoll), TNF, NSC-635257; Interferon gamma (Genentech), IFN-G, NSC-600662.” NCT00001296 ↗2“IFN-g (interferon-gamma) 3 x 100 - 150 µg/week s.c. has been succesfully administered.” NCT00244179 ↗ “interferon gamma (IFN-G)” NCT00002637 ↗ |
| Known as | IFN-gamma | “Recently, it has been shown that in vivo administration of interferon gamma (IFN-gamma) upregulates CD18 expression in normals and alters leukocyte trafficking.” NCT00001905 ↗ |
| Known as | IFN-y | “HIV gag-pol antigens and interferon-gamma (IFN-y) in diluent” NCT00332930 ↗ |
| Known as | IFN-γ | “The administration of interferon gamma (IFNγ) can restore the level of mHLA-DR and may possibly improve the prognosis as an adjuvant therapy associated to antibiotics.” NCT05843786 ↗3“adjunctive immune-stimulatory therapy with interferon-gamma (IFN-γ) may represent a promising candidate” PMID 24669841 ↗ Mar 2014 “a single injection of DNX-2401 was followed by interferon gamma (IFN-γ).” NCT02197169 ↗ “Interferon-gamma (IFN-γ): starting dose 50 mcg/m2 subcutaneously” NCT02614456 ↗ |
| Known as | Immukine | “Interferon-gamma (Immukine, Boehringer-Ingelheim, Alkmaar, the Netherlands), 100mcg subcutaneously, on days 0-2-4-7-9-11.” NCT01649921 ↗ |
| Known as | interferon gamma-1b | “Group 1 will receive 500 micrograms of interferon gamma-1b 3 times a week for 48 weeks by inhalation.” NCT00021567 ↗ |
| Known as | NSC-600662 | “Tumor Necrosis Factor (Knoll), TNF, NSC-635257; Interferon gamma (Genentech), IFN-G, NSC-600662.” NCT00001296 ↗ |
| Known as | recombinant interferon gamma | “Biological: recombinant interferon gamma” NCT00004032 ↗ |
| Known as | recombinant interferon gamma 1b | “recombinant interferon gamma 1b (rIFN-gamma1b)” PMID 19264351 ↗ Mar 2009 |
| Known as | rIFN-g | “rIFN-g (Interferon Gamma)” NCT00501644 ↗ |
| Known as | rIFN-gamma1b | “interferon gamma 1b (rIFN-gamma1b)” PMID 19264351 ↗ Mar 2009 |
| Known as | rIFN-γ | “treated with recombinant IFN-γ (rIFN-γ, 100 μg s.c., thrice a week) for 2 weeks” PMID 24669841 ↗ Mar 2014 |
| Known as | TG1041 | “Adenovirus-Interferon- Gamma (TG1041)” NCT00004016 ↗ |
| Action | Activate | “interferon gamma (IFN-gamma) upregulates CD18 expression in normals” NCT00001905 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Gamma Interferon” NCT00001317 ↗ |
| Route | Subcutaneous | “subcutaneous injections of interferon-gamma” NCT00001317 ↗ |